Mediwatch secures five year global distribution agreement with Inverness Medical Innovations

19-Mar-2009 - United Kingdom

Mediwatch plc has signed a five-year agreement for the worldwide distribution of PSAwatch, its flagship point-of-care total PSA measuring system for prostate cancer, with Inverness Medical Innovations, Inc. According to the company, Inverness has an extensive global sales-force which will complement Mediwatch’s own worldwide distribution network and provide the Company with considerably more market reach.

Philip Stimpson, Mediwatch Chief Executive commented: “We are confident that this strategically important distribution agreement will deliver a significant revenue stream. The market for point of care diagnostics is growing rapidly as a result of a combination of; the population aging, growth of local clinics, home testing and the need for faster, cheaper, more portable and easier to use medical equipment. "

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures